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Background: The objective was to find evidence to substantiate assertions that electronic applications for
medication management in ambulatory care (electronic prescribing, clinical decision support (CDSS), electronic
health record, and computer generated paper prescriptions), while intended to reduce prescribing errors, can
themselves result in errors that might harm patients or increase risks to patient safety.
Methods: Because a scoping search for adverse events in randomized controlled trials (RCTs) yielded few relevant
results, we systematically searched nine databases, including MEDLINE, EMBASE, and The Cochrane Database of
Systematic Reviews for systematic reviews and studies of a wide variety of designs that reported on
implementation of the interventions. Studies that had safety and adverse events as outcomes, monitored for them,
reported anecdotally adverse events or other events that might indicate a threat to patient safety were included.
Results: We found no systematic reviews that examined adverse events or patient harm caused by organizational
interventions. Of the 4056 titles and abstracts screened, 176 full-text articles were assessed for inclusion. Sixty-one
studies with appropriate interventions, settings and participants but without patient safety, adverse event outcomes
or monitoring for risks were excluded, along with 77 other non-eligible studies. Eighteen randomized controlled
trials (RCTs), 5 non-randomized controlled trials (non-R,CTs) and 15 observational studies were included. The most
common electronic intervention studied was CDSS and the most frequent clinical area was cardio-vascular, including
anti-coagulants. No RCTS or non-R,CTS reported adverse event. Adverse events reported in observational studies
occurred less frequently after implementation of CDSS. One RCT and one observational study reported an increase in
problematic prescriptions with electronic prescribing
Conclusions: The safety implications of electronic medication management in ambulatory care have not been
established with results from studies included in this systematic review. Only a minority of studies that investigated
these interventions included threats to patients’ safety as outcomes or monitored for adverse events. It is therefore not
surprising that we found little evidence to substantiate fears of new risks to patient safety with their implementation.
More research is needed to focus on the draw-backs and negative outcomes that implementation of these
interventions might introduce.
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E-prescribing or the e-prescription (e-Rx) is defined in the
Center for Medicare and Medicaid Services’ “final rule” as
“…. the transmission, using electronic media, of prescrip-
tion or prescription-related information between a pre-
scriber, dispenser, pharmacy benefit manager, or health
plan, either directly or through an intermediary, in-
cluding an e-prescribing network” [1]. The implementa-
tion of e-Rx has been heralded as a remedy for problems
associated with paper-based prescribing that can result in
suboptimal or harmful outcomes for patients (e.g. [2]).
The world’s first e-Rx for an ambulatory patient was trans-
mitted from a physician’s office to a community pharmacy
in Sweden in 1983 and by the end of 2008 it was estimated
that about 80% of all new prescriptions in ambulatory care
in Sweden were e-Rxs [3]. Other implementations of
e-prescribing are in the USA [4] and Norway [5]. Canada
is hoping “to make e-prescribing a reality by 2015” [6]. In
addition to the e-Rx, the electronic health record (EHR)
and clinical decision support systems (CDSS), both
e-applications that can support clinicians’ prescribing activ-
ities, have been widely implemented and are regarded as
important means to reduce the number of errors in medi-
cation management. CDSSs are implemented with the
intention of improving clinical decision making in diagnosis
and treatment [7], often for the purpose of changing pro-
vider behaviour (e.g. [8]); or supporting rational decision
making and/or accurate use of clinical logarithms [9,10].
Systems with advanced clinical decision support inte-
grated with the EHR have been acclaimed and supported
by research as the interventions most likely to reduce ad-
verse events in medication management; e.g. drug-drug
interactions, allergic reactions and faulty dose calculations;
to support adherence to best practice and to best support
clinical decision making e.g. [11-16].
Why there is a need for a systematic review
Despite the above accolades, concern has been expressed
that digital applications might facilitate or provide new op-
portunities for prescribing errors and adverse events (AEs)
or adverse drug events (ADEs) (e.g. [2,17]. Errors have been
attributed to those that occur during input and access of in-
formation, and to communication and coordination pro-
cesses between coupled applications or between application
and end-user [18]. Examples of errors are faulty algorithms
for dose calculation; wrong default dosing or route;
user-interface facilitated errors; fragmentation errors due to
faulty integration between applications; programming er-
rors; as well as “false expectations” of clinicians who rely too
whole-heartedly on the system’s capabilities [13,17,19-21].
Our scoping literature search did not identify systematic
reviews or randomized studies in the field that might sub-
stantiate these assertions. One review that classified out-
come type found only four of 30 included studies (1950 toMarch 31, 2006) that assessed safety [22]. Another [23]
lists adverse drug events (ADEs) and deaths as patient
outcomes and identifies the studies in which AEs and
monitoring for AEs were specified à priori. Although we
found relevant reviews that explored the effectiveness and
efficiency of organizational interventions (e.g. CDSS) on
improving process or patient outcomes (e.g. [15], to our
knowledge, there is no earlier systematic review of which
the main objective is to identify adverse events or harms
to patients caused by organizational interventions.
Objectives
The objective for this review was to gather evidence that
might substantiate assertions that implementation of e-
interventions for medication management in ambulatory
care introduces new risks to patient safety.
Methods
Criteria for considering studies for this review
Types of studies eligible for this review
There is little guidance on methods to conduct systematic
reviews to answer questions about adverse effects, adverse
events or patient harms albeit a few methodological re-
views explore the challenges (e.g. [24,25]) and the merits
of including various study designs (e.g. [26,27]).
Randomized controlled studies are underused in evalu-
ating medical informatics interventions because of con-
straints, e.g. “(1) ethical considerations, (2) difficulty of
randomizing subjects, (3) difficulty to randomize by loca-
tions ......., (4) small available sample size” [28]. In line with
this, our preliminary scoping search failed to locate any
randomized controlled trials (RCTs) of e-applications in
medication management in ambulatory care of which the
object was to discover or measure adverse events or risks
to patient safety. There is also convincing evidence that
harms or adverse events are inadequately reported by ran-
domized trials [29]. It is proposed that information on
harms from both long-term prospective studies as well as
RCTs should be used in identifying harms [26].
Based on the above and observations of other authors
[30-34], we decided to include a wide assortment of
study designs: randomized controlled trials (RCTs); non-
randomized trials with concurrent control (n-RCTs);
controlled trials; uncontrolled or non-concurrent con-
trolled trials; cohort studies; cross-sectional studies and
other observational designs.
Interventions, settings and participants
Interventions
The intervention had to comprise at least one of the fol-
lowing e-applications:
– electronic transmission of individual patients’
prescriptions to a pharmacy or digital prescription
repository accessible to community pharmacies (e-Rx),
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prescriber’s computer (CGPRx) meant to be
retrieved at the community pharmacy by the patient
or her care giver,
or
– at least one of the following e-applications used at
point-of-care and in real time during medication
management, with or without e-Rx or CGPRx,:
digital clinical decision support systems (CDSS).
electronic health record (EHR).
In the research and discussion literature, the terms “e-
prescribing” and “computerized prescribing” are sometimes
interchangeably used to label medication management sys-
tems that might comprise one or more IT applications. For
example, a system designated as “electronic prescribing”
used “electronic prescribing software” with “clinical deci-
sion support” to generate either a paper or a digital pre-
scription [35]. Occasionally, it is not clear exactly which
e-applications are operative when the label “e-prescribing”
is used without more specification, e.g. [36].
In this review we define an electronic prescription
(e-Rx) as the digital message sent by an authorized pre-
scriber to a pharmacy or a digital prescription repository
that is accessible to community pharmacies. A telefax
to a pharmacy is one of the simplest forms of an e-
prescription. E-prescribing is the act of using electronic
information processing, usually the personal computer
(pc), to generate the e-prescription.
In this review we define CDSS as electronic access, via
stationary or portable computer, including appliances like
Palm Pilot, to any information that supports clinicians’
prescribing or monitoring of a patient’s medication regime
at point-of-care [37] from simple drop-down formulary
lists (so-called passive decision support) to sophisticated
systems that access patient-specific data from the EHR
and e.g. use clinical algorithms to compare prescribing to
a knowledge base, generate patient-specific recommenda-
tions or trigger tailored e-alerts to the prescriber in real
time, i.e. at the time of medication management (so-called
active decision support). In summation, CDSS in this
review includes all e-applications that support selec-
tion or dosing regimens of medications or monitoring
of parameters relevant for medication management
(therapeutic drug monitoring). Examples of CDSS are
electronic reminders, alerts, medication pick-lists, for-
mularies, dose calculators, medication regime manage-
ment suggestions or guideline presentation. A CDSS
can be stand-alone or coupled to the EHR and/or an
e-prescribing application.
We use the Health Information Management System’s
Society’s definition of the EHR [38]:“The Electronic Health Record (EHR) is a longitudinal
electronic record of patient health information gener-
ated by one or more encounters in any care delivery
setting.”
Setting and participants
We included publications written in English or a
Scandinavian language published after 1994 that reported
effects of or observations associated with the imple-
mentation of the e-applications under consideration and
implemented in ambulatory care, (i.e. doctors’ offices, out-
patient clinics, emergency rooms, well-baby clinics), tar-
geted at the clinician, (i.e. health practitioners authorized to
prescribe medications, i.e. nurses, nurse practitioners, phys-
ician assistants, and physician) for the purpose of medica-
tion management in the broad sense, i.e. new prescribing
(including vaccinations) or medication regime adjustments:
or activities performed for the purpose of evaluation and
modification of patients’ therapeutic pharmacological re-
gime, e.g. monitoring of relevant physiological and drug
parameters. Eligible participants were doctors or nurses
licensed or otherwise eligible to prescribe medications
in the setting.
Outcomes
We included studies that reported quantifiable objective
outcome measures and comprised:
– Harms or threats to patient safety defined as
outcomes in the study methods section.
– Any adverse events, as defined by the investigators.
– Anecdotal reports of events that could signify
threats to patient safety.
Outcomes could be:
– Process of care: e.g. unsafe prescribing.
– Patient outcomes: e.g. mortality; morbidity, e.g.
major bleeds, thrombotic events; adverse drug
events (ADEs): e.g. unintended effects of drugs
including drug-drug and drug-disease interactions;
clinical course e.g. admission to specialist facility,
emergency room visit.
– Technological outcomes: e.g. errors in transmission,
errors in algorithm programming.
Criteria for exclusion were:
– studies performed in an in-patient setting or a
combination of in- and out-patient settings where
outcomes were not differentiated according to this
classification
– primary endpoints were subjective measures
(patients’ or clinicians’)
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e-interventions and outcomes were not differentiated
according to this classification
– studies where medication management outcomes
were part of a bundle that included non-medication
management outcomes and outcomes were not
reported according to this classification
– the intervention was not delivered at point-of-care,
in real-time and for an individual patient
– the intervention was only a direct order entry of a
medication to be administered by clinic staff, except
for immunizations
– simulated interventions
Strategy for identification of eligible studies
Electronic searches
We searched for systematic reviews, randomized con-
trolled trials, non-randomized controlled trials and obser-
vational studies that investigated the use of e-applications
in medication management in ambulatory care and re-
ported quantifiable outcomes. We performed systematic
searches for literature published from 1995 to 2012 in the
following databases: Ovid MEDLINE, Ovid EMBASE,
Ovid British Nursing Index, ISI Social Science/Science
Citation Index, Cochrane Database of Systematic Reviews,
Cochrane CENTRAL, Database of Abstracts of Reviews of
Effects (DARE), Health Technology Assessment Database
(HTA), PubMed and SveMed. The first search was per-
formed in September 2008 and was updated three times.
The last search was performed August 8, 2012 (Additional
file 1: Table S1).
The search strategy consisted of subject headings and
text words covering the concepts of electronic prescrip-
tions and decision support as well as related concepts like
medical informatics and electronic patient journal (EPJ)
(combined with “prescriptions/medication”). These search
terms were combined with terms for ambulatory care/
primary health care or patient safety. We also performed
a supplementary broad search in the Cochrane Central
EPOC register to retrieve all studies with the subject head-
ing “Information systems” (including subheadings).
Hand-searching
Hand searches were performed by one investigator (CLC)
for relevant studies, i.e. inspection of lists of included
studies from relevant systematic reviews (Additional file 2:
Table S2) and reference lists from discussion papers and
relevant studies.
Study evaluation for inclusion
Preliminary screening of the identified publications from
the first two and fourth systematic searches was carried
out independently by pairs of researchers (EJP & CLC
and CLC & TKD, respectively) who evaluated relevanceby reading abstracts and when no abstract was available,
based on the title or full text version. One reviewer (CLC)
evaluated titles and abstracts found on the third system-
atic search. We retrieved full-text articles for all studies
judged as relevant. Two researchers (CLC & TKD) inde-
pendently evaluated studies in their full-text version for
inclusion and we discussed and agreed upon inclusion of
the studies.
Data extraction and management
Two authors (CLC & TKD) extracted estimates and fund-
ing data from randomized controlled trials. There was no
disagreement between reviewers. One author (CLC) en-
tered these estimates plus the following data into SPSS
data bases for all studies: study design; setting; participants;
objectives; intervention; comparator; and any relevant ob-
served outcomes. For all studies, we recorded anecdotal
reports of unexpected or adverse events that were reported
to have or in the investigators’ or authors’ opinion, could
have signified or caused compromises to patient safety.
Study quality of the included RCTs was assessed independ-
ently, discussed and agreed upon by two investigators
(CLC & TKD).
Quality assessment
Two reviewers (CLC, TKD) independently assessed,
discussed and agreed upon the quality of the RCTs
using a supplemented version of the EPOC checklist [39]
(Additional file 3: Table S3). We did not assess quality for
the other study designs.
Results
Results of search and selection process
We obtained full-text articles for 159 publications by
screening titles and abstracts of the 3941 unique studies
identified by systematic searches, plus another 17 studies
identified from hand searching reference lists in relevant
studies and systematic reviews, giving a total of 176 poten-
tial studies for inclusion. We did not find any system-
atic reviews that examined adverse events or harms to
patients caused by organizational interventions. One-
hundred thirty-seven of these studies were excluded
(Figure 1). Thirty-six of these excluded studies were RCTs
with relevant interventions, participants and settings but
either had no outcomes that were directly related to risks
to patient safety, did not report any adverse events or did
not monitor for them. As well, 3 non-R,CTs and 21 obser-
vational studies were excluded for this reason (Figure 1;
Additional file 4: Table S4; Additional file 5: Table S5;
Additional file 6: Table S6).
We included 39 individual studies, comprising three
study design groups: RCTs (n = 18); non-R,CTs (n = 5); and
observational studies (n = 16) (Additional file 7: Table S7;
Additional file 8: Table S8; Additional file 9: Table S9).
Figure 1 Flow chart of search and selection process.
Carling et al. BMC Medical Informatics and Decision Making 2013, 13:133 Page 5 of 10
http://www.biomedcentral.com/1472-6947/13/133Randomized controlled trials (n = 18)
Description of included RCTS
Eighteen randomized controlled trials specified outcomes
related to safety, e.g. “unsafe prescribing”, “error rate”, had
adverse events as outcomes, or specified à priori that
monitoring for adverse events was planned [35,40-56].
Settings for these 18 RCTs were doctors’ offices (n = 9;
50%), hospital out-patient (n = 6; 33%), both doctors’ of-
fices and hospital out-patient clinics (n = 1; 6%), and emer-
gency room (n = 2; 11%) (Additional file 10: Table S10).
E-Rx was investigated in only one RCT, a pragmatic trial
[35] along with user-initiated CDSS and an e-application
to print paper prescriptions (eGPP). All RCTs investigated
CDSS, whereof the CDSS was system-initiated in 16 stud-
ies and user-initiated in 2 studies. Uptake of intervention,
adherence or non-override of CDSS advice was poor in six
of the eight studies that reported this. In all the 10 studies
where it was apparent that a EHR was in operation, it was,
or appeared to be, in the same digital environment as the
CDSS application. In all, eGPP was mentioned to be in
use in two RCTs [35,40].
The most frequent drug classes and clinical areas studied
were anti-coagulants (5 studies) [42-44,49,56]; other cardio-
vascular or heart disease management (n = 4) [40,46,48,54],
and elderly patients (n = 4) [45,50-52]. Most of the RCTs
were funded by non-industry grants or similar. We found a
risk of funding bias in only one study [43]. Quality assess-
ment of included RCTs is provided in Additional file 11:
Table S11.
Outcomes for RCTs
Eleven studies had adverse events or serious negative re-
sults as main outcomes [40,43,44,46-49,51,54-56]. One of
these showed a statistically higher estimated risk of “car-
diovascular events” (based on surrogate markers) whenCDSS was compared with a risk chart but no significant
differences when the compared was with traditional dos-
ing. However, no actual adverse events were reported, des-
pite explicit monitoring for them [48]. Reduction in risk of
injury was statistically significant in [51] and there were
statistically significant improvements for heart failure pa-
tients’ outcomes in [40] and three of seven outcomes for
asthma patients [47]. In the remaining studies, there were
no significant differences or so low event incidence that
calculation of significance was meaningless.
Problematic prescribing or prescriptions (e.g. unsafe/risky
prescribing, prescribing errors, unclear prescription) were
the outcomes of seven studies [35,41,42,45,50,52,53]. Sig-
nificantly better results for the intervention group were
found in five studies [41,42,45,50,52,53], significantly worse
results were found in one study [35] and non-significant
differences in the remaining study.
Non-randomized controlled studies (n = 5)
Of the five included studies, three investigated CDSS
[57-59], one investigated computer-generated paper pre-
scriptions [11], and one investigated e-prescribing [60].
All studies investigated prescribing errors and one included
potential adverse drug events as an outcome [11]. No study
found any adverse events and other outcomes were either
better or unchanged in all studies. One study reported that
all errors in the CDSS intervention group were concordant
with override of decision support advice [58] (Additional
file 12: Table S12).
Observational studies (n = 16)
Fifteen studies had the following pre-specified outcomes:
faulty, risky, unclear prescriptions or prescriptions with
errors (n = 11) [61-71], unclaimed e-prescriptions (n = 2)
[72,73], and adverse drug events (ADEs) (n = 3) [62,74,75].
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outcome of overriding alerts because the authors reported
that the only three ADEs that occurred in the study were
consistent with alert non-compliance [76]. In addition,
ADEs were anecdotally reported in [63]. Of the four stud-
ies that reported before-and-after ADEs, there were fewer
ADEs after implementation of computer generated paper
prescriptions in one study [74] and better or unchanged
incidence after implementation of CDSS in two studies
[62,75]. Three adverse events were related to interacting
drug prescriptions where the prescriber did not comply
with CDSS advice [77]. E-prescribing was evaluated in
three studies [61,72,73]. Only one study [61] showed a re-
sult in disfavor of the e-intervention, in that more clarifi-
cations were needed by pharmacists for e-prescriptions
than for non-e-prescriptions. Two of these studies re-
ported that some patients who did not retrieve their e-
prescribed drugs at the pharmacy said this was because
they had no paper prescription to remind them [72,73]. In
one of these [73], 33% of the unclaimed prescriptions were
for “essential drugs. User-interface problems were reported
as the cause of prescribing error in two studies. A non-
controlled before-and-after study found errors in CDSS
pick-lists and wrong information concerning available for-
mulations and duration of treatment [74]. A retrospective
survey reported high rates of discrepancies between free-
text and check-off fields on e-prescriptions, of which in-
vestigators assessed that 16% of discrepancies could lead
to hospital admission or death [67] (Additional file 13:
Table S13).
Discussion
Randomized and non-randomized controlled trials did
not show any adverse patient events. The incidence of
adverse events/adverse drug events did not increase post-
intervention in observational studies. The quality of pre-
scriptions was significantly worse in only one RCT [35]
and one pre-post observational study [61]. One non-R,CT
reported all prescribing errors were concordant with over-
ride of the CDSS advice [58].
From the studies assessed in this review, it appears
that observational studies give us most insight into po-
tential causes of adverse events or potential for patient
harm. User-interface, faulty programming and erroneous
information in the CDSS application were problems that
lead to erroneous prescribing [67,74]. Adverse events were
found to be concordant with non-adherence to CDSS sug-
gestions [77]. Some patients forgot to pick up e-prescribed
drugs for important medications because they had no
paper reminder [72,73].
Contrary to the “false expectation” hypothesis, presented
in the introduction, that excessive reliance on or confidence
in an e-application for medication management would fa-
cilitate errors or adverse events, there was low compliancewith CDSS advice among the eight RCTs that reported this,
consistent with other’s findings [76,78] and all adverse
events in two studies were concordant with CDSS non-
compliance [58,77]. This may be due to professionals’ skep-
ticism or fear of loss of autonomy, e.g. [79].
Limitations to the review
As far as we are aware, this is first systematic review to
focus on the risks and adverse outcomes of e-interventions
for medication management in ambulatory care settings.
Its findings, however, are limited, and should be inter-
preted with caution. We did not find randomized or non-
randomized studies of which the main objective was to
evaluate the safety, or, conversely, the risks associated with
implementation of e-interventions for medication manage-
ment in ambulatory care. Only one observational study fo-
cused on “unintended consequences” [67]. Although we
used an all-inclusive approach, scrutinizing studies of al-
most any design where an e-intervention was used, only a
minority of the individual studies we initially assessed for
inclusion were concerned with safety issues at all. Sixty-
five percent of the 99 studies with appropriate interven-
tions, settings and participants that we assessed did not
investigate, monitor for or mention anecdotally adverse
events or risks to patient safety and therefore were not in-
cluded in this review. Sixty-six per cent (36) of otherwise
eligible RCTs were excluded for this reason, leaving only
18 RCTs for inclusion. Unfortunately, even where adverse
events are not the main study outcomes, RCTs are appar-
ently often not powered to reveal seldom or beforehand
unknown outcomes or do not have a long-enough or
appropriate follow-up. Even non-significant findings of
adverse events may indeed have clinical significance, espe-
cially if they were made available for meta-analysis [80].
Publication bias [81,82] and funding bias might also con-
tribute to the dearth of published studies investigating or
reporting adverse events or patient safety outcomes.
Weaknesses of the review
It is possible that we did not locate all relevant studies in
our searches. Firstly, of studies found in the third system-
atic search, screening of titles and abstracts, and selection
of studies for which to obtain full-text publications was
conducted by only one researcher. Secondly, harm or ad-
verse effects are often inadequately reported in the re-
search literature, poorly indexed in the medical databases
and might be difficult to identify. Therefore, searching for
adverse effects requires highly sensitive search filters with
several different subject headings and text words [25,83].
It is difficult to create effective adverse effects search fil-
ters; therefore better reporting and indexing of adverse ef-
fects is required [25]. To overcome this issue, we made a
parallel search, not restricted to adverse effects, but for
studies performed in ambulatory care settings. However,
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clinical research setting in their abstracts and there is in-
consistent use of terminology [84]. There are constantly
new studies being published on this topic and it is possible
that updates of this review might alter conclusions.
Conclusions
As so few studies were looking for them, it is not sur-
prising that we found little evidence that might substan-
tiate assertions that implementation of e-applications in
medication management in ambulatory settings causes or
introduces new untoward risks, adverse events or harms to
patients. Until more evidence is sought and presented to
disprove the apparently prevailing assumption of the null
hypothesis that the e-interventions do not introduce risk, it
is premature to conclude that we can fail to reject it.
Implications for practice
The safety implications of e-medication management in
primary care have not been established with results from
existing studies found in this systematic review. Regard-
ing, however, the substantial investment necessary to im-
plement e-technologies for medication management and
the potential for improving decision making and quality
of care, it would be prudent for health care providers to
consider attributes of interventions that might have been
shown to induce uptake of the intervention or reduce
override of CDSS advice (e.g. [85]). For example, there is
some evidence that user-initiation of the e-application and
forced justification of overrides might facilitate uptake.
Paper reminders for prescription redemption might help
patients remember to claim their e-prescribed medications
at the pharmacy [72,73]. Faulty programming of CDSS
might facilitate patient harm [74] while programming
built-in constraints into e-applications might eliminate po-
tentially dangerous rule violations and discrepancies [67].
Implications for research and reporting of research
Well-designed RCTs are needed to investigate hypothe-
sized untoward and adverse effects of e-interventions for
medication management in ambulatory care. It has been
suggested that a before and after clustered RCT utilizing
an incomplete block design is the optimal approach to
evaluate CDSS in primary care [86].
While harm outcomes may be the most sensitive and
valid endpoints to evaluate the implementation of systems
that effect safety, it is unethical in prospective studies to let
the consequences of professional or system errors reach
the patient. As well, in the real world, most prescribing er-
rors with potential to cause harm are intercepted before
they reach the patient. Surrogate endpoints established as
patient safety indicators might be employed. Factors instru-
mental to observed errors should be determined and allevi-
ated. Valid and reliable methods to assess the potentialseverity of errors and other surrogate end-points should be
developed.
Investigators conducting studies of the effect of orga-
nizational interventions should power their studies and
length of follow-up to capture rare, unintended and un-
suspected events and publish these findings regardless of
statistical significance. Even anecdotal reports of observed
risks to patient safety and adverse events can inform fu-
ture study hypotheses and design.
We encourage investigators to improve reporting quality
with use of the CONSORT statement, especially the ex-
tended version for cluster randomized trials [87]. In report-
ing studies of e-interventions for medications management,
authors should be explicit about which specific applica-
tions were studied, their features and implementation
strategy, and should consider using standard definitions.
As well, clearer descriptions of the study methodology
and more consistent use of study design labels would be
helpful to perform a more efficient search for observa-
tional studies [88].
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